AGN took a $535M (non-cash) charge in 1Q18 reflecting the worthlessness of the 2016 VTAE acquisition. The psoriasis program acquired from VTAE was recently canned due to toxicity.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”